MNG15
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.353
- OXIDATIVE_PHOSPHORYLATION+0.291
- PANCREAS_BETA_CELLS+0.282
- SPERMATOGENESIS+0.264
- PROTEIN_SECRETION+0.201
- ANDROGEN_RESPONSE+0.151
- ALLOGRAFT_REJECTION+0.138
- INTERFERON_ALPHA_RESPONSE+0.135
- INTERFERON_GAMMA_RESPONSE+0.103
- FATTY_ACID_METABOLISM+0.102
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.465
- APICAL_JUNCTION-0.422
- HEDGEHOG_SIGNALING-0.387
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.385
- MITOTIC_SPINDLE-0.359
- APICAL_SURFACE-0.343
- MYOGENESIS-0.326
- CHOLESTEROL_HOMEOSTASIS-0.260
- NOTCH_SIGNALING-0.247
- UV_RESPONSE_DN-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG85 | — | — | 0.809 |
| 2 | SRR8518285 | — | C | 0.786 |
| 3 | SRR25617825 | — | C | 0.785 |
| 4 | TCGA-EW-A1J6-01A-11R-A13Q-07 | — | B | 0.779 |
| 5 | TCGA-44-3917-01A-01R-A278-07 | — | cohortMD2 | 0.755 |
| 6 | d7472c45-93c1-4237-82ac-c17e863b9a58 | — | — | 0.754 |
| 7 | ERR2208973 | — | — | 0.741 |
| 8 | R355 | — | — | 0.741 |
| 9 | 66b4502b-d393-4664-a317-430ec1ad4b3b | — | — | 0.727 |
| 10 | 3c62910d-9304-40bd-a286-d3c1fa199d89 | — | — | 0.722 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.353 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.291 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.282 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.264 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.201 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.151 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.138 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.135 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.103 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.102 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.087 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.081 | Inavolisib | — uncovered |
| PEROXISOME | 0.076 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.040 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.015 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.009 | Inavolisib | — uncovered |